Trial Profile
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Omidubicel (Primary)
- Indications Acute myeloid leukaemia; Burkitt's lymphoma; Chronic myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell leukaemia; T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Gamida-Cell
- 01 Dec 2023 Results of secondary analysis (n=108) assessing Hospitalization and Healthcare Resource Utilization of Omidubicel Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies published in the Transplantation and Cellular Therapy
- 27 Sep 2023 According to a Gamida-Cell media release, company announced that the first patient has received a stem cell transplant with Omisirge.
- 01 Aug 2023 Results of sub-study assessing the immune reconstitution kinetics following HCT with omidubicel compared with UCB published in the Transplantation and Cellular Therapy.